BUZZ - Acumen shares plunge after mid-stage trial failure for Alzheimer's drug

Latest Updates

October 30 - ** Acumen Pharmaceuticals (ABOS.O) shares plunged 85% in premarket trading to $0.34

** The biotechnology company said its experimental intravenous drug sabirnetug for Alzheimer's disease failed to meet the primary goal in a mid-stage study, showing no significant effect versus placebo in slowing memory and functional decline

** The company said key secondary measures, including CDR-SB, also failed to reach statistical significance

** While the drug reduced brain amyloid plaque levels, this did not translate to a clinical benefit

** ABOS’s R&D pipeline includes an early-stage subcutaneous formulation of sabirnetug and a preclinical project to enhance brain delivery in collaboration with Japan’s JCR Pharmaceuticals 4552.T

** The company plans to halt development of sabirnetug, discontinue the extension phase of the study, and implement cash preservation measures

** As of the close of the previous trading day, the stock was up about 9% year-to-date

(To facilitate non-native English speakers, Reuters provides automated translations of its reports into several other languages. Because automated translation may contain errors or lack relevant context, Reuters does not guarantee the accuracy of these automated translations and provides them for readers' convenience only. Reuters accepts no responsibility for any damage or loss caused by the use of the automated translation function.)